Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BBP-418 (ribitol) in LGMD2I/R9
NL-OMON60387Phase 3Active, not recruiting
- Sponsor
- ML Bio Solutions
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ribitol in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by ML Bio Solutions. Primary endpoints: Change from baseline in NSAD at 36 months, Frequency and severity of TEAEs and TESAEs and 3 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NL-OMON60387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60387.